Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.
